Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
    • بيانات النشر:
      Publication: [Philadelphia, PA] : Taylor & Francis
      Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989-
    • الموضوع:
      Autoimmune Diseases/*complications ; Immunologic Factors/*therapeutic use ; Multiple Myeloma/*complications ; Multiple Myeloma/*drug therapy ; Thalidomide/*analogs & derivatives; Adult ; Aged ; Aged, 80 and over ; Autoimmune Diseases/diagnosis ; Hematopoietic Stem Cell Transplantation ; Humans ; Incidence ; Lenalidomide ; Male ; Middle Aged ; Multiple Myeloma/pathology ; Multiple Myeloma/therapy ; Neoplasm Staging ; Retrospective Studies ; Thalidomide/therapeutic use ; Treatment Outcome
    • نبذة مختصرة :
      Immunomodulatory drugs (IMiDs) may favor autoimmune disease (AD) occurrence. We conducted a retrospective study to evaluate AD occurrence among IMiD-treated patients with myeloma. Patients were grouped into three classes depending on the type of IMiD engaged. The first group included patients treated with thalidomide (Thal) (n = 474), the second group with lenalidomide (Len) (n = 140) and patients in the third group were first treated with Thal followed by Len (Thal-Len) (n = 94). Absolute risk of AD was 0.4% for patients treated with Thal, 4.3% for Len and 1.1% for Thal-Len. ADs manifested prevalently as autoimmune cytopenias (55%), although we observed one vasculitis, one optic neuritis, one Graves' disease and one polymyositis. ADs occurred preferentially in the first months of IMiD treatment. A previous autologous transplant was shown to be a significant risk factor. All ADs were managed with IMiD discontinuation and steroids, resolving in a few weeks, except for Graves' disease and polymyositis.
    • Comments:
      Comment in: Leuk Lymphoma. 2014 Sep;55(9):1962-3. (PMID: 24304420)
      Comment in: Leuk Lymphoma. 2015 Feb;56(2):550. (PMID: 25110822)
      Comment in: Leuk Lymphoma. 2015 Feb;56(2):548-9. (PMID: 25120052)
    • Contributed Indexing:
      Keywords: Multiple myeloma; autoimmune diseases; lenalidomide; thalidomide
    • الرقم المعرف:
      0 (Immunologic Factors)
      4Z8R6ORS6L (Thalidomide)
      F0P408N6V4 (Lenalidomide)
    • الموضوع:
      Date Created: 20140416 Date Completed: 20150423 Latest Revision: 20190116
    • الموضوع:
      20240628
    • الرقم المعرف:
      10.3109/10428194.2014.914203
    • الرقم المعرف:
      24730540